Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen

Patients with Gleason 8-10 cancer and PSA levels of<4.0 ng/ml have more aggressive disease than those with PSA levels of 4 to 9.9 ng/ml; these low PSA cancers behave more like those with PSA levels of 10 to 19.9 ng/ml. Further study is needed to evaluate potential biological differences in these patients with low PSA-producing cancers.